Skip to content

Investigational

Amycretin

Novo Nordisk

A single molecule that switches on both GLP-1 and amylin receptors — the same two targets as CagriSema, but as one molecule rather than two drugs combined. A weekly injection and a daily pill are both in development.

Investigational — not approved or available to prescribe.

Main trial result

22%

Phase 1b/2a (subcutaneous) · 20 mg weekly, 36 weeks

Stage

Phase 2 → 3

Timeline (not confirmed)

2028+ (estimated — not confirmed)

Form

Weekly injection or daily pill

What it is

A single molecule that switches on both GLP-1 and amylin receptors. It hits the same two targets as CagriSema, but as one molecule rather than two drugs combined. A weekly injection and a daily pill are both in development. The early data shows exceptional promise: oral Phase 1 results came in ahead of oral semaglutide.

Why this matters:

Early oral data shows promise, but this is still Phase 1 and 2 data only. Larger Phase 3 trials will be the real test. These treatments are still under investigation, and results in larger trials may differ from early data.

Was this page helpful?
Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment. Prices shown are United States self-pay or list prices and vary by insurance and country.

Development stage and timeline

Current stage:

Phase 2 is complete for the injection, the oral form, and T2D. Phase 3 trials in obesity start in Q1 2026. Phase 3 in T2D is also planned.

Next milestone:

Phase 3 obesity trials enrolling 2026. Phase 3 T2D trials planned. Estimated approval: 2028+ (very preliminary; not confirmed).

How it works

One molecule designed to switch on GLP-1 receptors, which cut appetite and slow the stomach. It switches on amylin receptors too, which cut appetite and slow the stomach through brainstem pathways. Using a single molecule may make manufacturing simpler than a fixed-dose combination such as CagriSema.

Timeline note: The Phase 1 oral data showed significant weight loss within 12 weeks. The Phase 2 injection data covered 36 weeks

Early-stage data

Phase 1 and Phase 2 data only. Phase 3 trials are planned, but not yet complete. Treat these early results with caution.

Subcutaneous injection20 mg once-weekly · 36 weeks

In trial data, 22% mean weight loss vs. 2% weight gain in placebo (Phase 1b/2a)

Oral tablet2 × 50 mg daily · 12 weeks

In trial data, 13.1% weight loss vs. 1.1% placebo (Phase 1). Oral semaglutide reached about 6% at the same point.

Subcutaneous injection (T2D)Once-weekly (various doses) · 36 weeks

In trial data, 14.5% weight loss in the Phase 2 T2D trial. 89.1% of patients reached HbA1c — a measure of average blood sugar over recent months — below 7%. Mean HbA1c drop of 1.8%.

Side effects (early-stage data)

Frequencies from Phase 2 trial data. Final Phase 3 safety profile may differ.

Nausea(40%)
Vomiting(20%)
Diarrhoea(18%)

Notable findings

  • ✓The pill showed 13.1% weight loss in 12 weeks — ahead of oral semaglutide at the same point (6%)
  • ✓Single molecule may be simpler to manufacture than CagriSema's two-drug combination
  • ✓Both injection and pill in development — offering a choice

What this tends to offer vs. what it involves

What this tends to offer

  • ✓Promising early data: 22% (injection) and 13.1% (pill) in small trials
  • ✓Single-molecule design simpler than two-drug combinations
  • ✓Both injection and oral pill in parallel development
  • ✓Oral formulation showing early signs of outperforming oral semaglutide

What this involves

  • Very early stage — Phase 1 and 2 data only
  • Phase 3 not starting until Q1 2026
  • Approval likely 2028+ — years away
  • No cardiovascular or long-term safety data yet

Community insights

These are personal experiences shared in public online communities — not medical advice.

“This is genuinely early — Phase 1 and small Phase 2 data only. The 22% and 13.1% numbers are exciting but from tiny, short studies.”

r/antiobesitymedication·Cautious perspective shared when early data was discussed

“The pill has no food timing restrictions, which comes up often as a key difference from oral semaglutide.”

r/antiobesitymedication·Thread comparing future GLP-1 + amylin formulations

Sources & references

  1. [1]
    Phase 1b/2a randomised controlled trial (subcutaneous)
    Adults with overweight or obesity · 36 weeks
    22% mean weight loss at 20 mg subcutaneous vs. ~2% weight gain in placebo. GI safety profile consistent with incretin class.
    Presented at EASD 2024 / Patient Care Online (2024) ↗
  2. [2]
    Phase 1 oral formulation trial
    Adults with overweight or obesity · 12 weeks
    13.1% weight loss at 2×50 mg/day vs. 1.1% placebo — exceeding oral semaglutide results at the same 12-week timepoint (~6%).
    EASD 2024 annual meeting / Patient Care Online (2024) ↗

Next step most people take

See what's available todayFDA-approved prescription treatments you can get nowHow GLP-1 drugs workPlain English explanation of the underlying mechanismCompare all optionsSee all treatment types side by side